PERIPARTAL KARDIOMIOPATIYA DILATATSION KARDIOMIOPATIYANING BIR SHAKLI SIFATIDA: YAQQOL SISTOLIK DISFUNKSIYA BILAN KECHGAN OG‘IR KLINIK HOLAT
##submission.downloads##
Peripartal kardiomiopatiya (PKMP) homiladorlikning oxirida yoki tug‘ruqdan keyingi ilk oylarda rivojlanadigan, hayot uchun
xavfli DKMP shaklidir. Maqolada 29 yoshli bemorda og‘ir PKMP holati keltiriladi: chap qorincha chiqarish fraksiyasi 23%, NYHA
bo‘yicha IV funksional sinf, Laun bo‘yicha IV A sinf qorincha ekstrasistoliyasi aniqlangan. Tashxis ExoKG, yurak MRT va
koronarografiya orqali tasdiqlandi. Sakubitril/valsartan, bisoprolol, dapagliflozin va spironolaktondan iborat terapiya fonida 6
daqiqalik yurish testi 50 m dan 410 m gacha oshdi, NYHA sinfi IV dan II ga yaxshilandi. Holat PKMPni erta aniqlash va tug‘ruqdan
keyingi davrda dinamik kuzatuv muhimligini ko‘rsatadi.
1. Roth G.A., Mensah G.A., Johnson C.O. et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am
Coll Cardiol. 2020. V. 76. № 25. P. 2982–3021.
2. Arbustini E., Behr E.R., Carrier L. et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023.
V. 44. № 37. P. 3503–3626.
3. Bauersachs J., König T., van der Meer P. et al. Pathophysiology, diagnosis and management of peripartum cardiomyopathy:
a position statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2019. V. 21. № 7. P. 827–843.
4. Sliwa K., Mebazaa A., Hilfiker-Kleiner D. et al. Clinical characteristics of patients from the worldwide registry on peripartum
cardiomyopathy (PPCM): EURObservational Research Programme. Eur J Heart Fail. 2017. V. 19. № 9. P. 1131–1141.
5. Абдуллаева Г.Ж., Абдуллаев А.А., Курбанов Р.Д. Молекулярно-генетические аспекты кардиомиопатий в
Узбекистане. Кардиология Узбекистана. 2022. Т. 3. № 1. С. 12–19.
6. Bello N., Rendon I.S., Arany Z. The relationship between pre-eclampsia and peripartum cardiomyopathy. J Am Coll Cardiol.
2013. V. 62. № 18. P. 1715–1723.
7. Hilfiker-Kleiner D., Kaminski K., Podewski E. et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum
cardiomyopathy. Cell. 2007. V. 128. № 3. P. 589–600.
8. Ware J.S., Li J., Mazaika E. et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med.
2016. V. 374. № 3. P. 233–241.
9. McDonagh T.A., Metra M., Adamo M. et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
failure. Eur Heart J. 2021. V. 42. № 36. P. 3599–3726.
10. Sliwa K., Petrie M.C., van der Meer P. et al. Clinical presentation, management, and 6-month outcomes in women with
peripartum cardiomyopathy: an ESC EORP registry. Eur Heart J. 2020. V. 41. № 39. P. 3787–3797.
11. McMurray J.J.V., Solomon S.D., Inzucchi S.E. et al. Dapagliflozin in patients with heart failure and reduced ejection fraction.
N Engl J Med. 2019. V. 381. № 21. P. 1995–2008.
12. Packer M., Anker S.D., Butler J. et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med.
2020. V. 383. № 15. P. 1413–1424.
Mulkiiyat (c) 2026 «O‘zMU XABARLARI»
Ushbu ish quyidagi litsenziya asosida ruxsatlangan Kreativ Commons Attribution-NonCommercial-ShareAlike 4.0 International litsenziyasi asosida bu ish ruxsatlangan..
.jpg)
.png)
